Design Therapeutics, Inc. DSGN Cash Flow Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| -$69.79M-40.7% | -$49.59M+25.8% | -$66.86M-5.6% | -$63.31M-78.2% | ||
| $622K+4.4% | $596K+11.0% | $537K+32.3% | $406K+215% | ||
| $14.55M+11.3% | $13.07M-0.1% | $13.09M+19.8% | $10.93M+133% | ||
| $4.49M— | —— | -$1.25M-123% | $5.4M— | ||
| —— | -$226K— | —— | $3.61M+255% | ||
| -$54.36M-26.1% | -$43.11M+26.4% | -$58.56M-14.1% | -$51.32M-74.7% | ||
| $193K— | —— | $256K-72.1% | $918K-40.3% | ||
| $291.78M+26.8% | $230.18M+2.4% | $224.7M— | —— | ||
| $314.89M+14.7% | $274.47M-1.1% | $277.5M+199% | $92.89M+172% | ||
| —— | —— | $52.54M+124% | -$220.99M-312% | ||
| $24.85M— | $0— | —— | $323K— | ||
| $25.74M+4,917% | $513K— | —— | $235K-99.9% | ||
| —— | —— | -$5.3M+98.1% | -$272.07M— | ||
| $3.25M-47.5% | $6.2M+1.9% | $6.08M+336% | $1.4M— | ||
| $622K+4.4% | $596K+11.0% | $537K+32.3% | $406K+215% | ||
| $4.49M— | —— | -$1.25M-123% | $5.4M— | ||
| —— | -$226K— | —— | $3.61M+255% | ||
| -$21K— | —— | —— | —— | ||
| $314.89M+14.7% | $274.47M-1.1% | $277.5M+199% | $92.89M+172% | ||
| —— | —— | $25K— | —— | ||
| $17K— | $0— | —— | —— | ||
| -$54.55M-25.6% | -$43.45M+26.1% | -$58.82M-12.6% | -$52.24M-69.0% | ||
| -$54.55M-25.6% | -$43.45M+26.1% | -$58.82M-12.6% | -$52.24M-69.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Design Therapeutics, Inc. generate?
- Design Therapeutics, Inc. (DSGN) generated -$54.0M in operating cash flow over the trailing twelve months.
- What is Design Therapeutics, Inc.'s free cash flow?
- After $121.0K of capital expenditures, Design Therapeutics, Inc.'s free cash flow was -$54.1M over the trailing twelve months, down 13.5% year over year.
- Where does Design Therapeutics, Inc.'s cash flow data come from?
- Every line is extracted from Design Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.